Edition:
India

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,154JPY
19 Jan 2018
Change (% chg)

¥19 (+0.31%)
Prev Close
¥6,135
Open
¥6,161
Day's High
¥6,205
Day's Low
¥6,139
Volume
890,500
Avg. Vol
1,303,985
52-wk High
¥6,465
52-wk Low
¥5,337

Select another date:

Fri, Dec 15 2017

BRIEF-R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

BRIEF-Shionogi to repurchase shares and retire treasury shares

* Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding

BRIEF-UMN Pharma says business and capital alliance with Shionogi

* Says it signed business and capital alliance agreement with Shionogi & Co Ltd on Oct. 31

BRIEF-Shionogi and Purdue Pharma announce U.S availability of Symproic (naldemedine)

* Shionogi inc - co, Purdue Pharma L.P. announce that Symproic (naldemedine) 0.2 mg tablets are now available throughout United States​

BRIEF-Shionogi says Lusutrombopag met primary, secondary endpoints in phase 3 study​‍​

* Shionogi & Co Ltd - ‍ Lusutrombopag met primary and all pre-specified important secondary endpoints in a global phase 3 study​

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO, Sept 20 Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

BRIEF-Shire and Shionogi announce positive topline results for Intuniv ​

* ‍SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Shionogi ‍announces positive top-line results for S-033188 phase 3 study

* Shionogi - ‍announces positive top-line results for s-033188 phase 3 study (capstone-1) in otherwise healthy influenza patients

Select another date: